The Tisch Cancer Institute

The Tisch Cancer Institute Scholars Program

We live in a time of unprecedented discovery about cancer. More than ever before, advances in genetics, immunology, and cell biology are enabling a deeper understanding of cancer prevention, care, and treatment. We imagine a future where this knowledge offers limitless potential to better treat and even cure cancer. The Tisch Cancer Institute Scholars Program (TCI Scholars) redoubles the efforts of our already high-quality cancer research program through fresh approaches from up-and-coming scientists.

Our TCI Scholars program provides promising early- and mid-career investigators at the Icahn School of Medicine at Mount Sinai with annual awards to support their innovative cancer research.  

By supporting TCI Scholars, you can:

  • Fund a critical need: Young investigators face limited options for funding from traditional sources such as the National Institutes of Health (NIH). The TCI Scholars program enables these promising scientists to put their research plan into action quickly.
  • Ensure Mount Sinai retains the brightest minds in cancer research: Donors to the TCI Scholars program provide the kind of flexible, reliable funding that helps recruit the most brilliant investigators to Mount Sinai—and keep them here.
  • Fund groundbreaking research at the outset: Fueled by early support, TCI Scholars will be better positioned to receive larger grants, publish their findings in leading journals, and train the next generation of researchers. Your contribution will enable our young investigators to put their research plans into action and accumulate the preliminary data—and establish credibility—to take their translational research from concept to actualization. As a result, patients will have access to innovative new treatments sooner.

The TCI Scholars Program funds the following:

Specific cancers including:

  • Breast & Gynecologic Cancers
  • Liver & Colon Cancers
  • Prostate Cancer
  • Lung Cancer
  • Multiple Myeloma
  • Lymphoma/Leukemia

Specific approaches including:

  • Immunotherapies
  • Genomics
  • Prevention & Early Detection

The TCI Scholars Program is open to early- to mid-career cancer faculty throughout the Mount Sinai Health System who are doing cancer-related research. We are particularly interested in projects designed with the goal of generating the preliminary data needed to secure external funding from the NIH or other sources. We select TCI Scholars on a competitive basis by an expert review committee led by Ramon Parsons, MD, PhD, Director of The Tisch Cancer Institute, who will ensure that the process is objective, thorough, and balances support for basic, clinical, and translational research. 

Meet Our Scholars

TCI scholars are involved with a wide variety of projects. With your support, our promising young investigators, like those below, will help advance research that directly affects our patients and those around the world.

Samantha Cohen, MD, Assistant Professor, Gynecologic Oncology: Dr. Cohen is a founding member of the Ovarian Cancer Translational Research Program that began at Icahn Mount Sinai and is now a multicenter consortium. Her research focuses on developing a personalized approach to ovarian cancer detection and treatment. Dr. Cohen has a particular interest in using next-generation sequencing to discover novel genetic changes in ovarian cancer.

Arvin Dar, PhD, Associate Professor, Oncological Sciences, and Pharmacological Sciences, and Associate Director of the Mount Sinai Center for Therapeutic Discovery: Dr. Dar conducts research to develop new therapeutic approaches for disease, particularly small-molecule modulators for targeting RAS-driven cancers.

Emily Gallagher, MD, PhD, Assistant Professor of Medicine (Endocrinology, Diabetes and Bone Disease) and Associate Program Director of the Internal Medicine Residency Program: Dr. Gallagher focuses on onco-endocrinology and recently received a K08 Mentored Clinical Scientist Research Career Development Award from the NIH/National Cancer Institute to study the role of hyperlipidemia in breast cancer progression. She is also Director of the Research Track for the Internal Medicine Residency Program.

Ernesto Guccione, PhD, Associate Professor, Oncological Sciences, and Pharmacological Sciences: Dr. Guccione’s research explores the basic mechanisms of transcriptional and post-transcriptional regulation in order to identify therapeutic opportunities in oncology. He is also the co-director of The Tisch Cancer Institute Next Bioinformatics Core for Generation Sequencing (BiNGS).

Amaia Lujambio, PhD, Assistant Professor, Oncological Sciences, a member of The Tisch Cancer Institute, and a member of the Precision Immunology Institute at Icahn Mount Sinai: Dr. Lujambio is investigating the mechanisms of liver cancer initiation and liver cancer maintenance.

Thomas Marron, MD, PhD, Assistant Director of Immunotherapy and Early Phase Trials at The Tisch Cancer Institute and Assistant Professor of Medicine (Hematology and Medical Oncology) at Icahn Mount Sinai: Dr. Marron leads numerous clinical trials for thoracic malignancies and hepatocellular carcinoma (liver cancer). He also leads the phase 1 trials program at The Mount Sinai Hospital, where he enrolls patients into dozens of trials focused on development of novel cancer immunotherapies.